Vimal Mehta - Dec 14, 2023 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role: CEO and President, Director
Signature: /s/ Richard Steinhart, as Attorney in Fact for Vimal Mehta, Ph.D.
Stock symbol: BTAI
Transactions as of: Dec 14, 2023
Transactions value $: $0
Form type: 4
Date filed: 12/18/2023, 04:55 PM
Previous filing: Sep 18, 2023
Next filing: Apr 8, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BTAI	Common Stock	Options Exercise		+2.61K	+8.81%		32.2K	Dec 14, 2023	Direct	F1
holding	BTAI	Common Stock						2K	Dec 14, 2023	By spouse
holding	BTAI	Common Stock						8.55M	Dec 14, 2023	By BioXcel LLC	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BTAI	Restricted Stock Units	Options Exercise	$0	-2.61K	-10%	$0.00	23.5K	Dec 14, 2023	Common Stock	2.61K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2	These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC and Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.
F3	On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.